Opinion
Video
Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering new hope for patients while requiring thoughtful integration into clinical practice and health care systems.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.